IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

This study tests a combination of immunotherapy drugs — interleukin-2 (IL-2), ipilimumab, and nivolumab — for patients with advanced melanoma (skin cancer) whose disease progressed after treatment with a PD-1 checkpoint inhibitor (such as nivolumab or pembrolizumab). **You may be eligible if...** - You have been diagnosed with Stage III (inoperable) or Stage IV melanoma - Your melanoma has gotten worse despite previous treatment with a PD-1 immunotherapy drug - You have not had active brain metastases recently (or they have been treated and are stable) - You have not received cancer treatment or radiation in the past 3 weeks - You have recovered fully from any prior surgery **You may NOT be eligible if...** - Your cancer has not previously been treated with a PD-1 checkpoint inhibitor - You have active, untreated brain metastases - You have significant heart disease or other major organ problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.